Incyte announced positive topline results from its two pivotal Phase 3 trials, TRuE-V1 and TRuE-V2, evaluating the safety and efficacy of ruxolitinib cream in adolescent…
An investigator employed by the University of Arkansas for Medical Sciences (UAMS) received a five-year $1.7 million grant to study the pathogenesis of pulmonary infection.…
Dr. Saurabh Chattopadhyay at University of Toledo recently received a five-year grant worth $2.2 million from the National Institutes of Health (NIH) to support the research…
The National Institute of Allergy and Infectious Diseases (NIAID) recently announced promising results from a small but important study involving 30 recovered COVID-19 patients infected…
Despite pandemic, economic rollercoaster, nasty politics and a host of other challenges faced, things are looking brighter in delightful La Jolla, California over on Torrey…
University of Texas MD Anderson Cancer Center researchers along with a colleague from Genentech (Roche) and Seoul National University in Korea have found, based on…
NeuroGenesis and Hadassah Medical Center announced highly positive results from a placebo-controlled Phase 2 clinical trial assessing the impact of NG-01 autologous proprietary subpopulation of…
TG Therapeutics announced positive topline results from two global, active-controlled, Phase 3 studies, called ULTIMATE I & II, evaluating ublituximab compared to Aubagio (teriflunomide) in…
Gilead announced topline results from the Phase 2/3 CAPELLA trial evaluating lenacapavir versus placebo in heavily treatment-experienced patients with multidrug resistant HIV-1 infection. A statistically…
The National Cancer Institute (NCI) injected $2.6 million into research involving two studies led by Case Western Reserve University and Cleveland Clinic as part of…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
